Levipil Syrup contains Levetiracetam 100 mg/ml, an antiepileptic medication primarily indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This syrup formulation is particularly suitable for pediatric patients or individuals who have difficulty swallowing tablets. Levipil Syrup is administered orally, with dosage individualized based on patient age, weight, and clinical response, typically initiated at a low dose and gradually titrated to achieve optimal seizure control while minimizing adverse effects. Common side effects may include somnolence, dizziness, headache, and behavioral changes such as irritability or agitation. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Levipil Syrup should be used under strict medical supervision, and abrupt discontinuation is discouraged to prevent seizure exacerbation. It is important to monitor patients regularly for therapeutic efficacy and any adverse reactions. This medication should be stored at room temperature, protected from light and moisture, and kept out of reach of children.